|
| Details |
Case Code: CLBS138
|
| Case Length: 05 Pages |
| Period: 2009-2014 |
| Pub Date: 2015 |
| Teaching Note: Not Available |
| Subject :Business Strategy |
| Price:Rs.100 |
| Organization :-- |
| Industry :Gaming |
| Countries : India |
|
|
|
|
Zynga - Survival at Stake? |
|
|
|
|
|
|
| The case is about US-based gaming company Zynga Inc. (Zynga), which was founded in 2007. It pioneered social gaming with its popular games like Zynga Poker and FarmVille. Over the years its games grew highly popular and attracted million users and FarmVille went on to become the fastest growing social game. But the company was unable to maintain the momentum with the emergence of new mobile games. In July 2013, Don Mattrick (Mattrick) took over as CEO of the company, and released mobile versions of Zynga’s popular games. Still, the fall continued. Even after Mattrick had been at the helm for more than 16 months, the company was unable to come out with a hit game. Pressure was increasing on Mattrick to arrest the further downfall of the company. |
| Buy Now |
| To download this case click on the button below, and select the case from the list of available cases: |
OR
 |
|
|
| |
Issues: |
 |
- Understand how changing industry dynamics affect companies.
|
|
- Analyze transition into new technologies and its impact on existing players.
|
|
- Understand the need for long term strategy.
|
|
| Introduction |
| For the three months ended September 30, 2014, the US-based gaming company Zynga Inc. (Zynga) reported that its revenues had fallen by 13% to US$ 176.6 million compared to the third quarter of 2013. Though the revenues increased by 15 %, the EBITDA fell from US$ 14 million compared to the second quarter of 2014. There was a 9% drop in the number of Daily Active Users too. |
| Questions: |
1. What are the factors that contributed to the growth of Zynga?
2. From the facts given in the case what do you think of Zynga's long-term strategy?
3. What should Don Mattrick do to turn Zynga around? |
Keywords |
|
Sun Pharma Ranbaxy merger, Sun Pharma, Ranbaxy, Daiichi, ANDA, FDA, generic drug, regulatory issues, SEBI, CCI, acquisition, pharmaceutical industrys
* This caselet is intended for use only in class discussions.
** More comprehensive case studies are priced at Rs.200 to Rs.700 (US $5 to US
$16) per copy.
|
|
|
|
